ATRICURE INC (ATRC)
Health Care · medical devices · NASDAQ
AtriCure provides specialized surgical solutions and cryotherapy devices for the treatment of atrial fibrillation and the management of post-operative pain.
What ATRICURE INC does
AtriCure is a medical device company that develops surgical therapies and products for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its portfolio includes cardiac ablation devices for open-heart and minimally invasive surgical procedures, as well as cryotherapy-based nerve block probes to provide temporary relief from post-operative pain. The company sells its products globally to medical centers through both direct sales forces and international distributors.
Themes: atrial fibrillation (Afib) therapy, cardiac surgery, pain management, electrophysiology, minimally invasive surgery
Fundamentals
- Price$48.98 as of 2026-08-21 close
- Market cap$2.5B as of 2026-08-21
- 1-year return+37.1% 2025-08-21 close $35.73 → 2026-08-21 close $48.98
- P/E209.65 as of 2026-08-24
- Net margin+1.9% as of 2026-08-24
- Gross margin+76.3% as of 2026-08-24
- ROE+2.1% as of 2026-08-24
- Debt / equity0.13 as of 2026-08-24
- Revenue growth (YoY)+13.9% as of 2026-08-24
- Revenue CAGR (3y)+17.4% SEC XBRL
- Beta1.28 as of 2026-08-24
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
How ATRC compares in its sector
- price-to-earnings ratiotop 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ATRC is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
42.6 #1262 of 1,704 scored · #205 of 240 in Health Care
Trend 85th: it is trading 37.0% above its 50-day average, the short-term trend line; catalysts 54th: open-market insider buys in 90 days 14, the analyst consensus rating is unchanged since the prior reading; weakest is setup 30th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How ATRICURE INC looks technically
ATRICURE INC (ATRC) is trading 45.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 6 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 84, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is trading right at its highest price of the past year (its 52-week high). Trading volume is unusually light — only about 50% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 45.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +45.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $35.75 | $35.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $33.76 | $33.76 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 36.33. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 6 trading days ago — a "golden cross", a bullish long-term signal | 6 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 45.1% above | +45.1% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control | 44.2 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 84, in overbought territory (above 70) | 83.7 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($37.98 to $49.20) — its "stochastic" reading is 98 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 20 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.20 | $49.20 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.5% |
| Above the 52-week low | it is 93.1% above its 52-week low (its lowest price of the past year) | +93.1% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.5% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $89.18 (set on 2021-11-05) | $89.18 |
| Given back of the 52-week move | over the past year its closes ranged ($25.86 to $48.98), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $33.95 to $34.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 45.1% below its all-time high | -45.1% |
| Nearest price level | it is trading 12.4% above a support level at $42.89 — a price it turned at four times since 2025-01-29, most recently on 2026-01-08. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -12.4% |
| All-time low | its lowest closing price on record is $1.00 (set on 2009-04-24) | $1.00 |
| Above the all-time low | it is 4798.0% above its all-time low | +4,798% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 88% of the past ~6 months) | 88th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.78 between its high and its low — about 3.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.78 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $35.52 and $48.93 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $35.52 – $42.22 – $48.93 |
| Typical daily range (% of price) | its price moves about 3.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.6% |
| Stretch from the 200-day average | it is trading 8.5 daily ranges above its 200-day average price (45.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 50% of its 30-day average | 0.50× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.0% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 14 sessions ago and has not traded back through the level it left behind at 37.76 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 4.6% gap down opened on 2026-07-29 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 17 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 39.6 percentage points (the stock gained 42.0% while the market gained 2.3%) | +39.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 66.9 percentage points (the stock gained 70.0% while the market gained 3.1%) | +66.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 39.3 percentage points (the stock gained 50.3% while the market gained 11.1%) | +39.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 16.6 percentage points (the stock gained 37.1% while the market gained 20.5%) | +16.6% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 50% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.8% of the share price. | +49.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 50% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $32.55 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +50.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 21% above the average price paid since it last reported on 2026-07-23 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $40.57 — a volume-weighted average of daily closes over 22 sessions, not a true tick-by-tick VWAP. | +20.7% |
Price levels it has turned at before
ATRC last closed at $48.98 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $42.89 | Support | 12.4% below the last close | turned there four times · 2025-01-29 to 2026-01-08 |
| $38.79 | Support | 20.8% below the last close | turned there twice · 2025-02-03 to 2026-01-02 |
| $38.08 | Support | 22.3% below the last close | turned there 8 times · 2024-11-11 to 2025-10-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $36.33.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $36.59 and $39.07 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.70 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$47.33 range $36.00 – $55.00; median $50.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ATRC
- Consensus EPS estimate$0.01192 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Difficulty of treating Afib and variability in long-term procedural success.","Dependence on medical centers adopting surgical and hybrid ablation procedures.","Risks associated with international distribution and currency fluctuations."]
What changed in the latest 10-Q
AI-assisted comparison of ATRC's 10-Q filed 2026-05-06 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) adds: 'Any forward-looking statement speaks only as of the date made.' in the Forward-Looking Statements section
- Reworded:
- Year reference changed from 'December 31, 2024' (older filing 2025-10-30) to 'December 31, 2025' (newer filing 2026-05-06) in the opening paragraph reference to Form 10-K
- Year reference changed from 'December 31, 2024' (older filing 2025-10-30) to 'December 31, 2025' (newer filing 2026-05-06) in the Forward-Looking Statements section reference to Form 10-K
- Phrase 'This discussion and analysis are intended' (newer filing 2026-05-06) replaces 'This discussion and analysis is intended' (older filing 2025-10-30)
- Phrase 'differ materially' (newer filing 2026-05-06) replaces 'different materially' (older filing 2025-10-30) in the Forward-Looking Statements section
- Notes:
- Both source texts are truncated at the end, cutting off mid-sentence at 'our Form 10-K for the fiscal year ended December 31, [2025/2024] in "'; comparison of any content after this point is not possible
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 5 sells ($2M) — 5 selling insiders
- Last 90 days0 buys · 5 sells ($2M) — 5 selling insiders
- Last 180 days0 buys · 7 sells ($2M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ATRC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for ATRC from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding ATRC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 6,111,221
- Reported value $174,353,141
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ATRC had 3,864,377 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ATRC had 7.60% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.72 days to cover at the same settlement.
- Reported short interest (shares) 3,864,377
- Short interest (% of shares outstanding) 7.60%
- Prior settlement (shares) 4,864,713
- Reported change -20.56%
- Days to cover (reported) 3.72
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ATRC vs…
ATRICURE INC is found in…
Frequently asked questions
What does ATRICURE INC (ATRC) do?
AtriCure is a medical device company that develops surgical therapies and products for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its portfolio includes cardiac ablation devices for open-heart and minimally invasive surgical procedures, as well as cryotherapy-based nerve block probes to provide temporary relief from post-operative pain.
What sector is ATRICURE INC (ATRC) in?
ATRICURE INC (ATRC) is classified in the Health Care sector. Its industry is medical devices. It trades on NASDAQ.
Who are ATRICURE INC's (ATRC) competitors?
Notable peers of ATRICURE INC (ATRC) include Medtronic, Abbott Laboratories, Boston Scientific and Johnson & Johnson. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ATRC?
Yes — we hold 2 matched STOCK Act disclosures for ATRC from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ATRICURE INC (ATRC) overbought or oversold right now?
ATRICURE INC (ATRC) is currently in overbought territory (its 14-day RSI is 84, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ATRC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.